A composite antibacterial hydrogel dressing, a preparation method and an application method thereof are provided, which relate to the field of biomedical technologies. The composite antibacterial hydrogel dressing is made from the following raw materials in parts by weight: 8 to 22 parts of chitosan, 12 to 36 parts of carrageenan, 9 to 25 parts of 2-aminoisonicotinic acid, 3 to 8 parts of lactic acid, 4 to 10 parts of iodine and 6 to 15 parts of potassium iodide. The composite antibacterial hydrogel dressing has a good flexibility, a strong antibacterial effect, a long antibacterial time, no skin irritation, good application prospect in the field of medical wound repair, simple preparation process and easy industrial production.

Described herein are oxygen-enriched tamponade compositions comprising silicone oil or a perfluorocarbon and methods of their use in the repair of retinal detachment. Post-operative repair for retinal detachment can include enhanced wound healing as the result of the administration of the compositions described herein. The enhanced wound healing can include rescue of ischemic retinal tissue, surgery induced hypoxia, and reduction of unwanted scar tissue development and prevention of re-detachment of the retina after surgical repair.

A wound dressing includes: a structural material formed into a dressing; at least one immunomodulatory agent associated with the dressing; and a growth factor associated with the dressing. A wound dressing kit includes: a structural material formed into a wound dressing; an immunomodulatory agent; and a growth factor composition, wherein the structural material contains the immunomodulatory agent and/or the immunomodulatory agent is in a separate composition. A method of treating a wound in a tissue includes: applying an immunomodulatory agent to the wound; applying a wound dressing to the wound; and allowing the wound to heal with the immunomodulatory agent and wound dressing. The application of a growth factor can be before, during and/or after applying the wound dressing to the wound.

A material or biomaterial comprising silicic acid condensates having a low degree of cross-linking, and methods for its production are subject-matter of the invention. A method for the production of silicic acid structures having a low degree of cross-linking is disclosed, wherein a sol is produced, wherein further condensation is prevented when specific cross-linking of the silicic acid is reached, wherein, preferably, structures having a size of 0.5-1000 nm are produced, e.g. polyhedral structures or aggregates of the same. Further condensation can be prevented by means of mixing with a polymer. In one embodiment, this comprises nano-structured, silicon dioxide (SiO.sub.2) having a low degree of cross-linking that is embedded in a polymer matrix. The material can be used in medicine for therapeutic purposes, and can enter into direct contact with biological tissue of the body in this connection. This material herein enters into chemical, physical, and biological interactions with the corresponding biological systems. It can herein be decomposed, and can act as a supplier for the silicic acid required for metabolism. Furthermore, it can have a supportive or shielding effect. It can be present as a granulate, microparticles, fiber, and as a woven or nonwoven fabric produced therefrom, or as a layer on implants or wound dressings. The material can be used as a medical device or as a nutritional supplement.

A material or biomaterial comprising silicic acid condensates having a low degree of cross-linking, and methods for its production are subject-matter of the invention. A method for the production of silicic acid structures having a low degree of cross-linking is disclosed, wherein a sol is produced, wherein further condensation is prevented when specific cross-linking of the silicic acid is reached, wherein, preferably, structures having a size of 0.5-1000 nm are produced, e.g. polyhedral structures or aggregates of the same. Further condensation can be prevented by means of mixing with a polymer. In one embodiment, this comprises nano-structured, silicon dioxide (SiO.sub.2) having a low degree of cross-linking that is embedded in a polymer matrix. The material can be used in medicine for therapeutic purposes, and can enter into direct contact with biological tissue of the body in this connection. This material herein enters into chemical, physical, and biological interactions with the corresponding biological systems. It can herein be decomposed, and can act as a supplier for the silicic acid required for metabolism. Furthermore, it can have a supportive or shielding effect. It can be present as a granulate, microparticles, fiber, and as a woven or nonwoven fabric produced therefrom, or as a layer on implants or wound dressings. The material can be used as a medical device or as a nutritional supplement.

An acellular product may be derived from human placenta and may be used in various scenarios for wound healing. Because the product may be acellular, the product may be processed for storage and transportation with minimal degradation. The product may include various scaffolding such as biomaterials or human tissue, and the scaffolding may be infused with various plasmas and agents. The cell-free treatment may maintain the biological activity of many therapeutic agents found within cells and may possess multiple structural components to support cellular attachment. The structural components or scaffolds may function as a reservoir of highly diffusible chemotactic and cellular-programming factors that may be useful to treat injury and disease.

An acellular product may be derived from human placenta and may be used in various scenarios for wound healing. Because the product may be acellular, the product may be processed for storage and transportation with minimal degradation. The product may include various scaffolding such as biomaterials or human tissue, and the scaffolding may be infused with various plasmas and agents. The cell-free treatment may maintain the biological activity of many therapeutic agents found within cells and may possess multiple structural components to support cellular attachment. The structural components or scaffolds may function as a reservoir of highly diffusible chemotactic and cellular-programming factors that may be useful to treat injury and disease.

Wound dressings and wound inserts comprising substantially dry reactive agents, methods of forming wound inserts comprising dry reactive agents, and wound-treatment methods.

A tissue-derived hydrogel, as well as methods of making and using such hydrogels, are provided.

A water-soluble sealant composition and a method for preparing the same which includes: adding soluble silver salt to a polyacrylic acid (PAA) solution; adjusting the pH of the PAA solution to 7-7.4; and heating the PAA solution to 90-125? C. The PAA has a molecular weight between 1000 to 8000. The composition includes a cross-linked poly(acrylic) silver matrix having affinity to proteins. The silver salt can be silver nitrate and/or silver acetate. The matrix may create hydrophilic zones which bind proteins. The composition when in contact with proteins may form hexagonal packing complexes of rod-like poly(acrylic) particles and proteins. It may form a clot made of multi-layered grid structure. In some cases, the complexes create loops that form cells comprising proteins e.g., albumin. The proteins may be of a body fluid such as blood, lymph and combinations thereof. The composition may be applied for a medical condition such as hemorrhage and lymphorrhea.